Heart Attack Diagnostics Market by Test Types (Electrocardiogram, Blood Tests [Troponin and Creatine Kinase MB Isoenzyme] and Echocardiogram) and Regions (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2021 – 2028

The global heart attack diagnostics market size is estimated to expand at a considerable CAGR during the forecast period, 2021 – 2028. The growth of the market is attributed to rising prevalence of heart disease cases, increasing research & government initiatives, and increasing health expenditure.

Heart attack, also known as Myocardial Infarction (MI), is a type of heart disease that generally occurred when heart stops its normal function. Without proper medications or medical guidelines, patients with heart diseases have a high risk of heart attack or cardiac arrest that can cause death. The pathophysiology of heart attack includes tissue necrosis of myocardium layer of heart. Atherosclerosis, as a deposition of thrombotic plaques in the arteries, can cause ischaemia (reduced blood supply to tissues), which resulting in low oxygen supply known as hypoxia. Due to hypoxia, thrombotic plaques get deposited and cause tissue death in the layer of heart that ultimately cause myocardial infarction. Apart from this, some diseases and conditions are responsible for heart attack such as coronary artery disease (CAD), atrial fibrillation, cardiomyopathy, cardiomegaly, congestive heart failure, and angina pectoris. Among these, CAD is a major cause of heart attack. Symptoms related to heart condition include chest pain, pain in neck, and shortness of breath. According to World Health Organisation (WHO), heart attack caused around 17.9 million deaths globally.

Heart attack diagnosis includes different types of methods such as electrocardiogram (ECG), blood test, chest X-ray, echocardiogram, coronary catheterization or angiogram, and cardiac magnetic resonance imaging (cMRI). These methods can detect the conditions or chances of heart attack. Some of the common drug treatment for heart attack include aspirin, streptokinase, clopidogrel, rivaroxaban, nitro-glycerine, propranolol, captopril, and atorvastatin.

Market Trends, Drivers, Restraints, and Opportunities

• Rising incidence of CAD and heart stroke, growing number of aging populaces, and inactive lifestyle can fuel the market expansion in the upcoming years.
• Increasing tobacco consumption & alcoholism, rising prevalence of obesity and high blood pressure & diabetes, and improper diet are expected to boost the market expansion during the forecast period.
• The outbreak of COVID-19 pandemic has raised the demand for the heart attack diagnostic and rising awareness of heart disease patients who require regular diagnosis are projected to propel the market growth.
• High cost of heart attack therapy is acting a major challenge expected to hamper the market growth in the coming years.
• Rising research collaborations to develop advanced technology and increasing government initiatives for the development of healthcare infrastructure can create lucrative opportunities for the market expansion during the forecast period.

Scope of the Report

The report on the global heart attack diagnostics market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Global Heart Attack Diagnostics Market Segment Insights

Blood test segment is expected to grow at a rapid pace
Based on test types, the global heart attack diagnostics market is divided into electrocardiogram, blood tests, and echocardiogram. The blood tests segment is further subdivided into troponin and creatine kinase MB isoenzyme (CK-MB). The blood tests segment held a major market share in terms of revenue generation in 2020 and is expected to grow at rapid pace during the forecast period from 2021-2028. Wide uses of troponin blood test for detection of heart disease across the globe is projected to boost the blood test segment.

Asia Pacific is projected to accounts for a key share
In terms of regions, the market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America dominated the market in terms of revenue generation in 2020 and is projected to represent a key market share in the coming years. The regional market growth can be attributed to rising awareness and health expenditure on heart disease, desk-bound lifestyle, and adoption of advanced technology. However, Asia Pacific is projected to register a robust CAGR during the forecast period due to high incidence rate of heart disease, rising healthcare expenditure for cardiovascular diseases, and high aging populace in the region.

Segments

• Electrocardiogram
• Blood Tests
  • Troponin
  • Creatine Kinase MB Isoenzyme (CK-MB)

• Echocardiogram

• Asia Pacific
• North America
• Latin America
• Europe
• Middle East & Africa

• Siemens Healthcare AG
• Midmark Corporation
• Schiller AG
• Koninklijke Phillips N.V.
• Hitachi healthcare
• Toshiba International Corporation
• F. Hoffmann-La Roche Ltd.
• Abbott Laboratories Inc.
• Bio-Rad Laboratories Inc.
• Beckman Coulter, Inc.
• AstraZeneca
• Pfizer Inc.
• Danaher Corporation

Competitive Landscape

Some of the key players in the market are Siemens Healthcare AG; Midmark Corporation; Schiller AG; Koninklijke Phillips N.V.; Hitachi healthcare; Toshiba International Corporation; F. Hoffmann-La Roche Ltd; Abbott Laboratories Inc.; Bio-Rad Laboratories Inc; Beckman Coulter, Inc.; AstraZeneca; Pfizer Inc., and Danaher Corporation. Many of these key players are actively investing in research & development to develop new technologies and also actively engaged in various market strategies. Some of the key strategies adopted by players are product launches, mergers, partnerships, acquisitions, and expansion of production units to enhance their market position and expand their consumer base across the globe.

In May 2019, Abbott introduced a new technology for implantable cardiac monitor (ICM), which offered to observe cardiac pulse. In August 2015, Schiller AG developed CARDIOVIT FT-1 that proved to be useful for continuous monitoring of heart beat.